Skip to Content Skip to Search

Diversity in clinical studies

Our goal is to have clinical trials that are as representative and accessible as possible, as well as reflect patient populations experiencing the disease and intervention we are studying across age, race, ethnicity, sex and gender.

Female doctor dressed in scrubs talking to a female patient and her daughter

What is GSK’s commitment to diversity in clinical studies?

At GSK, we believe our clinical studies must reflect the diversity of populations who are most likely to benefit from our medicines or vaccines.  We know diseases and medicines can affect people differently depending on their genetic background, ethnicity, gender/sex, age, etc.

So, representing the real-world disease population in our clinical studies is important to ensure our data represents real-world outcomes. 

We’re focusing on improving clinical trial diversity through five key approaches: 

  • Characterizing the populations most likely to be affected with the disease and barriers to access
  • Engaging with communities and advocacy groups to build trust, enhance awareness and provide education and outreach
  • Understanding and advocating for current clinical trial diversity guidelines from agencies and professional organizations as well as from community and patient advocacy groups
  • Embedding scientific questions for population-related responses within study protocols
  • Training and supporting GSK staff and research collaborators for success in enrolling diverse populations in clinical studies

Explore innovations in medicines and healthcare from inside and outside our labs. Discover more about what we do, the people behind GSK and how we are working to change the face of healthcare.

Find out about our clinical studies process, how we work with doctors and volunteers throughout this process, and how to become a research volunteer.  

Back to top